Skip to main content
Top

Investigational New Drugs

Issue 1/2000

Content (8 Articles)

In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood

Olivier Combes, Jérôme Barré, Jean-Claude Duché, Laurent Vernillet, Yves Archimbaud, Michael P. Marietta, Jean-Paul Tillement, Saïk Urien

Development of Target-Based Antineoplastic Agents

Walter M. Stadler, Mark J. Ratain

Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Christian Manegold, Petr Zatloukal, Kurt Krejcy, Johannes Blatter

Current Approaches and Future Strategies for Pancreatic Carcinoma

Robert A. Wolff, Paul Chiao, Renato Lenzi, Peter W.T. Pisters, Jeffrey E. Lee, Nora A. JanJan, Christopher H. Crane, Douglas B. Evans, James L. Abbruzzese

Promising Approaches in Acute Leukemia

Jorge Cortes, Hagop M. Kantarjian

Instructions for Authors

Instructions to Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine